SN BioScience, has 20 years of experience in drug delivery technology and commercialization of anticancer and metabolic disease drugs.

Younghwan Park, CEO, majored in pharmacy and has about 20 years of experience in non-clinical, clinical, drug delivery research and commercial development in the pharmaceutical industry.

In particular, he has extensive experience in drug delivery technology based on pharmacokinetics and pharmacology, and then has led the commercialization of various anticancer and metabolic disease drugs.
Recently, he has dedicated in nano-drug delivery technology, such as liposome, micelle and nanoparticle, in terms of physicochemical properties, protein binding and indication of drugs.

Based on these experiences, he founded SN BioScience, and is currently leading overall research and development of the company.